



ELSEVIER

Contents lists available at ScienceDirect

Data in brief

journal homepage: www.elsevier.com/locate/dib

Data Article

Collecting data through high throughput *in vitro* early toxicity and off-target liability assays to rapidly identify limitations of novel thromimimetics

Massimiliano Runfola ^a, Simona Sestito ^a, Sheraz Gul ^{b, **},
Grazia Chiellini ^c, Simona Rapposelli ^{a, d, *}^a Department of Pharmacy, University of Pisa, Pisa, 56126, Italy^b Fraunhofer Institute for Molecular Biology & Applied Ecology – ScreeningPort, Hamburg, Germany^c Department of Pathology, University of Pisa, Pisa, 56126, Italy^d Interdepartmental Research Centre for Biology and Pathology of Aging, University of Pisa, Pisa, Italy

ARTICLE INFO

Article history:

Received 24 December 2019

Accepted 23 January 2020

Available online 31 January 2020

Keywords:Triiodothyronine
Thyronamine
TR β selective agonist
Fatty-liver disorder
Liver regeneration
ADME-Tox profile
Off-target liability
Screening

ABSTRACT

In order to rapidly identify the phenotypic profile and possible off-target liability effects of novel synthesized thromimimetics for selection of lead compounds for further optimization studies, we performed *in vitro* screening on a new small library of synthetic thromimimetics. A comprehensive panel of early toxicity assays comprising cytotoxicity on 4 different cell lines (osteosarcoma, U2OS; lung fibroblast, hTERT; human breast adenocarcinoma, MCF7; human embryonic kidney, HEK293), hERG liability, cytochrome P450 inhibition (CYP1A2, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 isoforms), and off-target liability against selected proteins (Aurora B kinase and phosphodiesterase PDE4C1) and epigenetic enzymes (HDAC4, HDAC6, HDAC8, HDAC9 & SIRT7). All the compounds were screened at 10 μ M in at least triplicate using well-established *in vitro* assays with readouts in luminescence or fluorescence polarization mode. The raw data were processed using Microsoft Excel and the Z' for each assay was calculated (acceptable Z' >0.40). The processed and normalized data were organized in tables and visualized using spider plots. The results which are reported in the present manuscript can be used in prediction

DOI of original article: <https://doi.org/10.1016/j.ejmech.2019.112006>.

* Corresponding author. Department of Pharmacy, University of Pisa, Pisa, 56126, Italy.

** Corresponding author.

E-mail addresses: Sheraz.Gul@ime.fraunhofer.de (S. Gul), simona.rapposelli@unipi.it (S. Rapposelli).<https://doi.org/10.1016/j.dib.2020.105206>2352–3409/© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

studies of early toxicity and off-target liabilities of other thyromimetics using *in silico* methods. The data reported herein support our research article entitled “Design, synthesis and biological evaluation of novel TR β selective agonists sustained by ADME-Toxicity analysis” by Runfola M., Sestito S., et al. [1]

© 2020 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Specifications Table

Subject	DRUG DISCOVERY
Specific subject area	Early toxicity and off-target liability
Type of data	Tables Figures Spider plots
How data were acquired	Protocols for early toxicity and off-target liability assays All <i>in vitro</i> assays were performed after optimization of the manufacturer's kit protocols as reported within the Materials and Methods section. Cytotoxicity effects were evaluated using the CellTiter-Glo (Promega Corp.). Cardiac toxicity was assessed using the Predictor™ <i>h</i> ERG Fluorescence Polarization Assay Kit (Thermo). For detection of CYP450 activity, the luminescence-based P450-Glo® (Promega Corp.) assay system was used. HDAC inhibition was determined using the homogeneous, single-addition, bioluminogenic HDAC-Glo® I/II assay (Promega Corp.) for HDAC6 and HDAC8 or the HDAC-Glo® 2A assay (Promega Corp.) for HDAC4 and HDAC9. Inhibition of SIRT7 enzyme was determined using the SIRT-Glo® assay (Promega Corp.). Inhibition of PDE4C1 was determined using the PDE4C1 assay (BPS Bioscience) and inhibition of Aurora B kinase was determined using the Kinase-Glo® Luminescent Kinase Assay Platform (Promega Corp.). Luminescence or fluorescence polarization measurements in the assays were made using an EnVision Multilabel 2103 or 2300 EnSpire Multilabel (PerkinElmer) reader. The raw data were processed and normalized relative to the High and Low controls using Microsoft Excel and visually organized into tables and spider plots, where data for each compound are reported as % inhibition.
Data format	Raw data: Microsoft Excel Analyzed data: Microsoft Excel
Parameters for data collection	The early toxicity and off-target liability assays were selected using the generally accepted criteria for progressing in the drug discovery value chain to the lead compound stage.
Description of data collection	All raw data collected were from luminescence or fluorescence polarization measurements in the early toxicity and off-target liability assays using an EnVision Multilabel 2103 or 2300 EnSpire Multilabel (PerkinElmer) reader. The raw data were processed and normalized relative to the High and Low controls using Microsoft Excel and visually organized into tables and spider plots, where data for each compound are reported as % inhibition. As additional quality control, the Z' for each were determined and these exceeded the minimum threshold of >0.40.
Data source location	Fraunhofer IME ScreeningPort Hamburg Germany
Data accessibility	With the article (Supplementary Material: “SM1_raw_data.xlsx” and “SM2_processed_data.xlsx”).
Related research article	Massimiliano Runfola, Simona Sestito, Lorenza Bellusci, Valeria La Pietra, Vincenzo Maria D'amore, Marta Anna Kowalik, Grazia Chiellini, Sheraz Gul, Andrea Perra, Amedeo Columbano, Luciana Marinelli, Ettore Novellino, Simona Rapposelli. (2020) <i>Design, synthesis and biological evaluation of novel TRβ selective agonists sustained by ADME-Toxicity analysis</i> . European Journal of Medicinal Chemistry, DOI/In Press.

Value of the Data

- The data are useful in evaluating compounds adequately when progressing them in the drug discovery value chain. In this case, we have evaluated novel therapeutic agents derived by chemical modifications of thyroid hormones.
 - The data would help investigators to optimize the design of new thyromimetics. Moreover, they could be used for predictive *in silico* models of early toxicity and off-target liability studies of thyromimetics.
 - The data would be expected to accelerate the development of pharmacological strategies to identify lead compounds with increased chances of progression in the drug discovery value chain.
-

1. Data description

Within this study we report data obtained from early toxicity and off-target liability studies together with assay protocols, raw and processed data for newly synthesized thyromimetics [1] as a powerful tool to rapidly identify new potential lead compounds with optimal properties for progression in pre-clinical drug discovery.

In Table 1, % Cytotoxicity or % Inhibition for each assay are reported as the average (AVG) from triplicate measurements together with the standard deviation (STD). The Z' is also reported for each assay.

Figs. 1–5 consist of data collected in Table 1 organized in the form of spider plots in order to optimize the visualization of generated data from each early toxicity and off-target liability assay.

Fig. 1 depicts the cytotoxicity effects assessed for each compound at 24 and 48 hours of treatment in different cell cultures.

In Fig. 2 data on metabolic interference of thyromimetics towards CYP450 isoforms are reported.

Fig. 3 depicts data collected on possible interaction between tested compounds and HDACs and SIRT7 activity, while Fig. 4 is a representation of inhibitory effect of tested compounds on Aurora B kinase and PDE4C1.

Finally, data collected on potential inhibitory effect of test compounds on *hERG* ion-channel are reported in Fig. 5.d

2. Experimental design, materials, and methods

2.1. Protocols for *in vitro* early toxicity and off-target liability assays

2.1.1. Cytotoxicity assays

Test compounds (10 μ M final concentration, 0.1% of DMSO), negative control (Valinomycin, 10 μ M final concentration, 0.1% of DMSO), or DMSO as positive control were dispensed using an Echo 550 Liquid Handler (20 nL/well) into white 384-well microtiter plates. Cell-lines (osteosarcoma, U2OS; lung fibroblast, hTERT; human breast adenocarcinoma, MCF7; human embryonic kidney, HEK293) were from ATCC and grown on surface-modified T175 cell culture flasks in Dulbecco's Modified Eagle Medium (DMEM) with 10% fetal bovine serum (FBS), 5% of L-glutamic acid, 5% of antibiotics (streptomycin and penicillin G). At about 80% confluency, cells were washed, trypsinized, and resuspended. Then, cells were counted in DMEM and seeded at 4000 cells/well (in triplicate) in plate containing test compounds and controls (20 μ L/well). Plates were incubated at 37 °C in presence of 5% CO₂ for 24 h or 48 h. Then again, 20 μ L/well of CTG detection mix from CellTiter-Glo Assay Kit (Promega Corp.) were added, and plates were gently mixed, incubated for 10-min in the dark and read using an EnVision Multilabel 2103 reader (PerkinElmer). Raw data were normalized to percentage of cell growth by using the corresponding NC containing only 0.1% v/v DMSO. The luminescence signal of each sample (S) was converted into percentage of cell growth compared with the average signal of NC. The following formula was used: % effect = $(S - PC)/NC \times 100$.

Table 1

Early toxicity and off-target liability profiles of compounds. For each assay the mean of three replicates (AVG), the standard deviation (STD), and the Z' for each assay are reported.

Compound	HEK293 % Cytotoxicity 24 h		HEK293 % Cytotoxicity 48 h	
	AVG	STD	AVG	STD
1	-8	3	-7	2
2	-5	2	2	2
3	-7	3	-5	2
4	7	3	11	2
5	1	1	1	2
6	17	5	15	4
7	-3	1	-6	0
8	2	1	4	3
9	10	3	9	3
10	-4	1	-3	0
11	-6	3	-5	3
Assay Z'	0.75		0.78	

Compound	hTERT % Cytotoxicity 24 h		hTERT % Cytotoxicity 48 h	
	AVG	STD	AVG	STD
1	1	1	1	2
2	-3	4	3	4
3	-2	7	-6	8
4	14	1	7	5
5	6	3	5	2
6	55	7	16	4
7	3	1	-1	5
8	3	7	0	8
9	13	3	7	3
10	4	4	-1	1
11	2	3	-2	5
Assay Z'	0.73		0.74	

Compound	MCF7 % Cytotoxicity 24 h		MCF7 % Cytotoxicity 48 h	
	AVG	STD	AVG	STD
1	6	35	0	7
2	10	8	11	1
3	9	11	-1	5
4	39	10	32	6
5	17	3	13	7
6	65	19	53	8
7	38	19	4	11
8	36	2	15	2
9	22	16	28	7
10	37	15	4	8
11	24	6	3	12
Assay Z'	0.45		0.65	

Compound	U2OS % Cytotoxicity 24 h		U2OS % Cytotoxicity 48 h	
	AVG	STD	AVG	STD
1	2	10	-6	3
2	-8	21	0	10
3	16	28	-4	3
4	0	12	14	2

Table 1 (continued)

Compound	U2OS % Cytotoxicity 24 h		U2OS % Cytotoxicity 48 h	
	AVG	STD	AVG	STD
	5	33	8	3
6	34	14	13	2
7	8	15	3	4
8	9	32	8	2
9	7	8	4	4
10	-2	6	4	1
11	2	7	3	4
Assay Z'	0.59		0.79	

Compound	CYP1A2 % Inhibition		CYP2C9 % Inhibition		CYP2C19 % Inhibition		CYP2D6 % Inhibition		CYP3A4 % Inhibition	
	AVG	STD	AVG	STD	AVG	STD	AVG	STD	AVG	STD
	1	48	48	13	5	7	4	-15	5	24
2	1	6	33	5	35	4	7	9	28	4
3	19	4	14	11	32	5	6	7	86	1
4	10	1	13	7	-2	7	-13	10	30	8
5	62	2	100	0	99	0	83	1	96	1
6	97	0	100	0	100	0	89	1	97	0
7	82	2	99	0	100	0	51	12	70	3
8	91	0	97	0	98	0	56	5	67	2
9	18	5	56	2	39	1	47	3	47	2
10	6	2	-3	2	-28	11	-30	14	-2	9
11	14	4	43	2	8	4	-15	29	9	7
Assay Z'	0.83		0.76		0.83		0.78		0.77	

Compound	HDAC4 % Inhibition		HDAC6 % Inhibition		HDAC8 % Inhibition		HDAC9 % Inhibition		SIRT7 % Inhibition	
	AVG	STD	AVG	STD	AVG	STD	AVG	STD	AVG	STD
	1	-15	0	-13	7	-2	2	-21	1	7
2	-12	1	-8	4	11	21	-14	1	5	2
3	-9	1	-20	18	1	3	-9	0	6	5
4	14	2	-19	11	17	1	4	5	5	9
5	-10	1	-15	10	-2	2	-10	1	6	3
6	-11	3	-32	3	1	4	-15	1	5	2
7	-7	1	-21	2	-2	2	-10	1	5	1
8	-2	3	-16	8	2	4	-2	3	-9	30
9	15	1	-26	8	12	2	11	4	10	7
10	-8	3	-17	5	3	2	-11	3	6	2
11	13	7	-33	14	5	4	21	2	9	1
Assay Z'	0.72		0.83		0.85		0.71		0.89	

Compound	Aurora B kinase % Inhibition		PDE4C1 % Inhibition	
	AVG	STD	AVG	STD
	1	6	1	7
2	3	2	23	20
3	4	2	31	4
4	14	3	15	2
5	7	4	26	14
6	4	5	23	32
7	10	6	45	20
8	8	3	17	16
9	18	6	17	8
10	14	3	15	2
11	18	6	18	8
Assay Z'	0.81		0.62	

Compound	hERG % Inhibition	
	AVG	STD
1	6	16
2	37	6
3	21	5
4	29	8
5	84	5
6	129	14
7	83	10
8	74	7
9	103	14
10	3	16
11	-19	16
Assay Z'	0.43	




Fig. 1. Cytotoxicity of new thymimetics. The % Cytotoxicity determinations were made in four different cell-lines (HEK293, hTERT, MCF7, and U2OS) at 24 h (red) and 48 h (yellow). See [Table 1](#) for further details.

2.1.2. hERG cardiotoxicity assay

Compounds were tested for potential cardiotoxicity (in triplicate) using The Predictor hERG fluorescence polarization assay (Thermo). 100 nL of the test/control compound was added to each well of an assay plate, followed by addition of 5 μ L homogenized membrane solution (undiluted) and 5 μ L of tracer (1 nM final concentration in assay). Then, plates were incubated for 2 h at 25 $^{\circ}$ C in a humidity-




Fig. 2. CYP450 liability of new thymimetics. % Inhibition of five CYP450 enzymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP3A4). See Table 1 for further details.




Fig. 3. Epigenetic off-target enzyme liability of new thymimetics. % Inhibition of epigenetic off-targets (HDAC4, HDAC6, HDAC8, HDAC9 and SIRT7). See Table 1 for further details.

controlled incubator, and the fluorescence polarization was measured using an EnVision Multilabel 2103 Reader (PerkinElmer). The NCs (0% inhibition) and positive controls with E-4031, a blocker of hERG-type potassium channels (yielding 100% inhibition), were used to normalize the raw data.

2.1.3. Cytochrome (CYP) P450 assays

These assays (at least in duplicate) make use of microsomal preparations of CYP450 (1A2, 2C9, 2C19, 2D6, and 3A4 isoforms) from baculovirus-infected insect cells (Corning Inc.) and cytochrome c reductase (and cytochrome b5 for CYP450 3A4). For detection of CYP450 activity, the luminescence-based P450-Glo (Promega Corp.) assay system was used that contained a luminogenic CYP450 substrate, lyophilized luciferin detection reagent, and reconstitution buffer. The substrates were luciferin derivatives of CYP450-specific substrates that produce (4S)-4,5-dihydro-2-(6-hydroxybenzothiazolyl)-4-thiazolecarboxylic acid (D-luciferin) after cleavage by CYP450 (CYP450 1A2 luciferin-ME; CYP450 3A4, luciferin-IPA; CYP450 2C19, luciferin-H EGE; CYP450 2C9, luciferin-H; CYP450 2D6, luciferin-ME




Fig. 4. Aurora B kinase and PDE4C1 off-target enzyme liability of new thymimimetics. % Inhibition of Aurora B kinase and PDE4C1. See [Table 1](#) for further details.




Fig. 5. hERG liability of new thymimimetics. % Inhibition of hERG. See [Table 1](#) for further details.

EGE). CYP450 reactions were initiated by addition of the NADPH regeneration system to the enzyme-substrate mixture with the luciferin detection reagent stopping the reaction and the D-luciferin being converted to oxyluciferin under production of light being proportional to the CYP450 activity. Compounds were added into an empty 384-well plate (10 nL/well in 0.1% v/v DMSO) using the Echo 550 Liquid Handler followed by addition of 5 μ L/well of CYP450/substrate mixture and incubation for 30 min at 37 °C, after which the reaction was initiated by addition of 5 μ L/well NADPH regeneration system. After a further 30 min incubation at 37 °C, the CYP450 reaction was stopped, and the luciferase reaction was simultaneously initiated by addition of 10 μ L/well of luciferin detection reagent, followed by an additional 30 min incubation at 37 °C. The luminescence signal was detected using an EnVision Multilabel 2103 reader (PerkinElmer).

2.1.4. HDAC4, HDAC6, HDAC8 and HDAC9 assays

Inhibition of HDAC enzymes (in triplicate) was determined using the homogeneous, single-addition, bioluminogenic HDAC-Glo I/II assay (Promega Corp.) for HDAC6 and HDAC8 or the HDAC-Glo 2A assay (Promega Corp.) for HDAC 4 and HDAC9. Human recombinant HDAC enzymes (BPS

Bioscience), and standard inhibitor trichostatin A (Sigma-Aldrich) was dissolved to a yield stock solution in 100% v/v DMSO and stored at -20°C . Plate handling was performed using an Echo 550 Liquid Handler and luminescence measurements taken using a 2300 EnSpire Multilabel reader (PerkinElmer). Test compounds and positive control (Trichostatin A with final concentration of $10\ \mu\text{M}$ and 0.1% v/v DMSO) and high control (final 0.1% v/v DMSO) were added into the 384-well plates ($10\ \text{nL/well}$; 0.1% v/v DMSO) using the Echo 550 Liquid Handler. Enzyme solutions containing optimized concentration of substrate and enzyme were prepared according to each kit. $5\ \mu\text{L}$ of each solution were added to each well (in assay concentrations were 0.002 nM for HDAC4, 2.5 nM for HDAC6, 0.2 nM for HDAC8, and 0.10.025 nM for HDAC9). The HDAC-Glo I/II assay reagent and HDAC-Glo 2A assay reagent were prepared according to each kit manual and $5\ \mu\text{L}$ of them were added to each well. The microtiter plates were mixed briefly by orbital shaking ($500\text{--}700\ \text{rpm}$), and luminescence was measured at steady-state signal: background, which was achieved after 20 min.

2.1.5. SIRT7 assay

Inhibitory effect of test compounds on SIRT7 enzyme (in triplicate) was determined using the SIRT-Glo assay kit (Promega Corp.). Human recombinant SIRT7 enzyme (BPS Bioscience). Plate handling was performed using an Echo 550 Liquid Handler and luminescence measurements taken using a 2300 EnSpire Multilabel reader (PerkinElmer). Test compounds and DMSO as control were added into the 384-well plates ($10\ \text{nL/well}$; final concentration of $10\ \mu\text{M}$; 0.1% v/v DMSO) using the Echo 550 Liquid Handler. SIRT-Glo reagent was prepared as described in the manual kit and added to each well after 20 min of incubation ($10\ \mu\text{L/well}$). The microtiter plates were mixed briefly by orbital shaking ($500\text{--}700\ \text{rpm}$), and luminescence was measured at steady-state signal: background, which was achieved after 30 min.

2.1.6. PDE4C1 assay

Inhibitory effect of test compounds on PDE4C1, a protein necessary to assure normal cell growth, was determined (in triplicate) using the PDE4C1 assay kit (BPS Bioscience). Test compounds ($10\ \text{nL}$, in assay concentration of $10\ \mu\text{M}$ and 0.1% v/v DMSO) and DMSO as control were dispensed into a black 384-well no-binding low-volume plate. Substrate and enzyme solution were prepared and $2.5\ \mu\text{L}$ of each mix were dispensed in each well, and the plate was gently mixed and incubated for 1 h at rt in the dark. Then, binding agent solution were prepared according to kit protocol, and $10\ \mu\text{L}$ of this solution were added to each well. The plate was then sealed, centrifuged and incubated for 20 min at rt with slow shaking. Fluorescence polarization measurement were performed on an EnVision Multilabel 2103 reader (PerkinElmer). Each signal was normalized to positive (100% inhibition, no substrate) and to negative control (0% inhibition, DMSO control).

2.1.7. Aurora B assay

Inhibitory effect of test compounds on Aurora B kinase was determined (in triplicate) using the Kinase-Glo[®] Luminescent Kinase Assay Platform (Promega Corp.). $5\ \text{nL}$ of compound dissolved in 100% DMSO and DMSO as control were dispensed to each well of a 384-well plate (final concentration $10\ \mu\text{M}$; final concentration of 0.1% v/v DMSO) using an Echo 550 Liquid Handler. An enzyme master mix containing $1\times$ buffer, $50\ \mu\text{M}$ DTT, and $300\ \text{nM}$ Aurora B (all reagents provided in the kit) was prepared and $2.5\ \mu\text{L}$ of solution were added to each well. $2.5\ \mu\text{L}$ of reaction mix containing of $1\times$ buffer, $3.33\ \mu\text{M}$ adenosine triphosphate (ATP), and $7.5\ \text{ng}/\mu\text{L}$ ($18.75\ \text{ng/well}$) myelin basic protein (MBP) as substrate (buffer and MBP were provided in the Aurora B Kinase Enzyme System (Promega Corp.); ultrapure ATP (Sigma Aldrich) were added to each well in order to start reaction. Plate was then sealed using thermowell sealing taper, briefly mixed, and incubated for 30 min at rt. Following this, $5\ \mu\text{L}$ of Kinase-Glo[®] Reagent were added to each well, the plate was then mixed and incubated at rt for 20 min, and luminescence measurements were read using a 2003 EnSpire Multilabel reader (PerkinElmer). The luminescence signal of each sample (S) was converted into percentage of Aurora B inhibition and compared with the average signal of no substrate (100% Inhibition).

Acknowledgments

We thank the COST action CA15135 (Multitarget Paradigm for Innovative Ligand Identification in the Drug Discovery Process MuTaLig) for support the working experience of MR at the Fraunhofer-IME SP (Hamburg, Germany). We also thank POR FSE 2014–2020 – Regione Toscana and the University of Pisa for financing the fellowship to SS.

Conflict of Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Appendix A. Supplementary data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.dib.2020.105206>.

References

- [1] M. Runfola, S. Sestito, L. Bellusci, V. La Pietra, V.M. D'amore, M.A. Kowalik, G. Chiellini, S. Gul, A. Perra, A. Columbano, L. Marinelli, E. Novellino, S. Rapposelli, Design, synthesis and biological evaluation of novel TR β selective agonists sustained by ADME-Toxicity analysis, *Eur. J. Med. Chem.* 188 (2020 Feb 15) 112006, <https://doi.org/10.1016/j.ejmech.2019.112006>.